eversyn GmbH Secures €1.6M Seed Round to Pioneer GMO-Free Biocatalysis Innovations from Max Planck Expertise

eversyn GmbH, a pioneering spin-off from the Max Planck Institute Magdeburg, is excited to announce that it has successfully raised €1,600,000 in its latest funding round. This significant investment—backed by current and former Max Planck scientists as well as experienced business professionals—will propel the company’s revolutionary work in biocatalysis and synthetic biology. At the heart of eversyn’s innovation is the proprietary technology that harnesses novel, GMO-free biocatalytic cascades. These processes have been meticulously designed and engineered to produce nucleotide sugars at a fraction of the current market costs, representing a transformative leap in efficiency and cost-effectiveness in the field. The recently secured funding will be strategically deployed to scale up production and further develop the company’s burgeoning portfolio. Building on the success of its nucleotide sugar production, eversyn is now engineering new biocatalysts aimed at synthesizing human milk oligosaccharides and fine-tuning the glycosylation of therapeutic proteins. By addressing these critical areas, the company is not only enhancing the manufacturing of essential biochemicals but also paving the way for improved therapeutic protein development—a breakthrough that holds promising implications for healthcare innovation. This funding milestone reflects the growing confidence in eversyn’s disruptive approach and underscores the value of its unique blend of scientific expertise and entrepreneurial spirit. As the company continues to challenge traditional production paradigms, it remains committed to creating sustainable, cost-effective solutions that can significantly impact both industrial bioprocessing and medical biotechnology in the years ahead.